60 related articles for article (PubMed ID: 24942506)
1. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
Voorhees PM; Manges RF; Sonneveld P; Jagannath S; Somlo G; Krishnan A; Lentzsch S; Frank RC; Zweegman S; Wijermans PW; Orlowski RZ; Kranenburg B; Hall B; Casneuf T; Qin X; van de Velde H; Xie H; Thomas SK
Br J Haematol; 2013 May; 161(3):357-66. PubMed ID: 23432640
[TBL] [Abstract][Full Text] [Related]
2. Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
Papanikolaou X; Szymonifka J; Rosenthal A; Heuck CJ; Mitchell A; Johann D; Keller J; Waheed S; Usmani SZ; Van Rhee F; Bailey C; Petty N; Hoering A; Crowley J; Barlogie B
Haematologica; 2013 Jul; 98(7):1147-53. PubMed ID: 23716540
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of different regimens and prognostic factors in patients with first relapsed multiple myeloma treated after front-line bortezomib, cyclophosphamide, and dexamethasone].
Chen M; Fan Q; Li H; Ma YP; Qin XQ; Suo XH; Yang C; Zhu TN; Duan MH; Han B; Wang SJ; Zhou DB; Zhuang JL
Zhonghua Nei Ke Za Zhi; 2023 Dec; 62(12):1436-1443. PubMed ID: 38044070
[No Abstract] [Full Text] [Related]
4. [Bendamustine combined with pomalidomide and dexamethasone in relapsed multiple myeloma with extramedullary disease: a multicenter study].
Wu HY; Zhou X; Chu XX; Deng XZ; Yuan CL; Ran XH; Liu GQ; Fan CB; Hao HY; Zhong YP
Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):667-671. PubMed ID: 37803841
[No Abstract] [Full Text] [Related]
5. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.
Shaughnessy JD; Zhou Y; Haessler J; van Rhee F; Anaissie E; Nair B; Waheed S; Alsayed Y; Epstein J; Crowley J; Barlogie B
Br J Haematol; 2009 Nov; 147(3):347-51. PubMed ID: 19702643
[TBL] [Abstract][Full Text] [Related]
6. How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma.
Morris TCM; Drake MB; Kettle PJ; McGuigan T; Leahy M; O'Dwyer M; Enright H; O'Shea T; Popat R; Oakervee HE; Yong K; Cavenagh JD; Cairns DA; Alvarez-Iglesias A; Cook G
Clin Hematol Int; 2021 Mar; 3(1):27-33. PubMed ID: 34595464
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of bortezomib plus dexamethasone in patients with refractory primary immune thrombocytopenia: A single-center study.
Liu LN; Cui YS; Fang BJ
Asian J Surg; 2023 Dec; 46(12):5482-5483. PubMed ID: 37541902
[No Abstract] [Full Text] [Related]
8. Evaluation of Cardiac Function before and after PAD Regimen in Patients with Multiple Myeloma by Three-Dimensional Speckle Tracking Imaging.
Chen D; Yan Z; Fan L; Rui Y
J Healthc Eng; 2022; 2022():1849969. PubMed ID: 35126904
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of Thalidomide combined with PAD Regimen in patients with multiple Myeloma.
Wang Y; Man QH; Li C
Pak J Med Sci; 2023; 39(5):1243-1248. PubMed ID: 37680825
[TBL] [Abstract][Full Text] [Related]
10. Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles.
Borisov N; Sergeeva A; Suntsova M; Raevskiy M; Gaifullin N; Mendeleeva L; Gudkov A; Nareiko M; Garazha A; Tkachev V; Li X; Sorokin M; Surin V; Buzdin A
Front Oncol; 2021; 11():652063. PubMed ID: 33937058
[TBL] [Abstract][Full Text] [Related]
11. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
Orlowski RZ; Gercheva L; Williams C; Sutherland H; Robak T; Masszi T; Goranova-Marinova V; Dimopoulos MA; Cavenagh JD; Špička I; Maiolino A; Suvorov A; Bladé J; Samoylova O; Puchalski TA; Reddy M; Bandekar R; van de Velde H; Xie H; Rossi JF
Am J Hematol; 2015 Jan; 90(1):42-9. PubMed ID: 25294016
[TBL] [Abstract][Full Text] [Related]
12. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.
Dimopoulos MA; Orlowski RZ; Facon T; Sonneveld P; Anderson KC; Beksac M; Benboubker L; Roddie H; Potamianou A; Couturier C; Feng H; Ataman O; van de Velde H; Richardson PG
Haematologica; 2015 Jan; 100(1):100-6. PubMed ID: 25261096
[TBL] [Abstract][Full Text] [Related]
13. Maintenance therapy for multiple myeloma.
McCarthy PL; Palumbo A
Hematol Oncol Clin North Am; 2014 Oct; 28(5):839-59. PubMed ID: 25212886
[TBL] [Abstract][Full Text] [Related]
14. Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
Moreau P; Hulin C; Facon T
Hematol Oncol Clin North Am; 2014 Oct; 28(5):829-38. PubMed ID: 25212885
[TBL] [Abstract][Full Text] [Related]
15. HMGB1 enhances chemotherapy resistance in multiple myeloma cells by activating the nuclear factor-κB pathway.
Ning J; Yang R; Wang H; Cui L
Exp Ther Med; 2021 Jul; 22(1):705. PubMed ID: 34007314
[TBL] [Abstract][Full Text] [Related]
16. Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
Zhou X; Steinhardt MJ; Grathwohl D; Meckel K; Nickel K; Leicht HB; Krummenast F; Einsele H; Rasche L; Kortüm KM
Cancer Med; 2020 Aug; 9(16):5819-5826. PubMed ID: 32608149
[TBL] [Abstract][Full Text] [Related]
17. Modified bortezomib, adriamycin and dexamethasone (PAD) regimen in advanced multiple myeloma.
Zhang Y; Liu H; Chen X; Bai Q; Liang R; Shi B; Liu L; Tian D; Liu M
Pathol Oncol Res; 2014 Oct; 20(4):987-95. PubMed ID: 24942506
[TBL] [Abstract][Full Text] [Related]
18. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
Lee SS; Suh C; Kim BS; Chung J; Joo YD; Ryoo HM; Do YR; Jin JY; Kang HJ; Lee GW; Lee MH; Shim H; Kim K; Yoon SS; Bang SM; Kim HY; Lee JJ; Park J; Lee DS; Lee JH;
Ann Hematol; 2010 Sep; 89(9):905-12. PubMed ID: 20349060
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
